NB: This webinar will be in English, will be recorded, and made publicly available online in due time.
Antimicrobial Resistance (AMR) is one of the most dangerous global public health issues. AMR is the phenomenon of treatment-resistant bacteria, infections, parasites or viruses, also known as superbugs. Antibiotic overuse is a key driver of AMR. The Guardian reported that AMR is now one of the leading causes of death worldwide, with Nature reporting 1.27 million deaths per year.
75% of the world’s antibiotics are used in livestock. Often antibiotics are routinely and systemically administered to livestock in order to prevent an infection from entering herds or to prevent it from spreading. There are initiatives active on the responsible use of antibiotics in livestock, but relatively little attention is being paid to the link between public health, animal welfare and AMR. In order to take action, in-depth knowledge of AMR, its associated (business) risks and what role institutional investors can play is needed.
In this webinar, experts on public heath, animal welfare and responsible investment will discuss antimicrobial resistance (AMR), how it is linked to public health and animal welfare, what risks AMR poses to institutional investors, why they should take action on AMR, and why animal welfare should have a pivotal role in activities on AMR.
We would appreciate it if you could fill out this short survey (estimated completion time 3 minutes) on how institutional investors address AMR in their RI policy and activities. We will use the results to inform the content of the webinar and further steps on this issue.
Collective engagement on AMR
Institutional investors interested in collective engagement on antimicrobial resistance, public health and animal welfare please contact Sara Heinsbroek.
This webinar has been made possible in collaboration with World Animal Protection. World Animal Protection is working with governments to ban the use of antimicrobials for group disease prevention or as a growth promoter; and with corporates to ensure that antibiotics are not being used routinely to prop up low welfare practices in their supply chains.